← Leaderboards
Jurgen Tiberius Rohr
Medical University Of South Carolina
$6,950,139
Attributed
$8,945,206
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $652.2K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,945,206 · 4
By mechanism
R01$8,945,206 · 4
Top collaborators
- Markos Leggas5 shared
- Oleg V Tsodikov5 shared
Others in their field
Top investigators on “Analog”
- David Heimbrook · Leidos Biomedical Research, Inc.$196,589,777
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Norman Wolmark · Nsabp Foundation, Inc.$51,982,954
- Robert Turner Schooley · University Of Colorado Denver$48,513,949
- Kenneth A Bloom · University Of Nebraska-Lincoln$46,979,168
- John Hobbs · Suny At Stony Brook$41,239,084
Research focus
AnalogAntineoplastic AgentsPharmaceutical PreparationsToxic EffectProteinsBiochemicalPlicamycinAnabolismOxygenasesInvestigationLeadSidePathway InteractionsCombinatorialEnzymesInterestGlycosyltransferaseGenerationsPolyketide SynthaseBaseTumorDesignSpecificityAnticancer Activity
Grant awards (30)
Mechanistic and pharmacologic studies of selective mithramycin analogues targeting EWS-FLI1 in Ewing sarcoma$551,064
R01 · FY2024 · CA
Mechanistic and pharmacologic studies of selective mithramycin analogues targeting EWS-FLI1 in Ewing sarcoma$579,770
R01 · FY2023 · CA
Mechanistic and pharmacologic studies of selective mithramycin analogues targeting EWS-FLI1 in Ewing sarcoma$592,330
R01 · FY2022 · CA
Mechanistic and pharmacologic studies of selective mithramycin analogues targeting EWS-FLI1 in Ewing sarcoma$617,234
R01 · FY2021 · CA
Mechanistic and pharmacologic studies of selective mithramycin analogues targeting EWS-FLI1 in Ewing sarcoma$652,202
R01 · FY2020 · CA
Exploring Post-Type II PKS Frame Modifications$276,355
R01 · FY2017 · GM · contact PI
Novel aureolic acid type antitumor agents$231,877
R01 · FY2017 · CA · contact PI
Exploring Post-Type II PKS Frame Modifications$276,739
R01 · FY2016 · GM · contact PI
Novel aureolic acid type antitumor agents$232,178
R01 · FY2016 · CA · contact PI
Exploring Post-Type II PKS Frame Modifications$277,123
R01 · FY2015 · GM · contact PI
Novel aureolic acid type antitumor agents$232,782
R01 · FY2015 · CA · contact PI
Exploring Post-Type II PKS Frame Modifications$276,719
R01 · FY2014 · GM · contact PI
Novel aureolic acid type antitumor agents$225,093
R01 · FY2014 · CA · contact PI
Novel aureolic acid type antitumor agents$239,862
R01 · FY2013 · CA · contact PI
Novel Aureolic Acid-Type Antitumor Agents$232,663
R01 · FY2012 · CA · contact PI
Novel Aureolic Acid-Type Antitumor Agents$232,663
R01 · FY2011 · CA · contact PI
Novel Aureolic Acid-Type Antitumor Agents$239,859
R01 · FY2010 · CA · contact PI
BIOSYNTHETIC KEY STEPS OF ANGUCYCLINE ANTITUMOR DRUGS$246,853
R01 · FY2009 · CA · contact PI
Novel Aureolic Acid-Type Antitumor Agents$239,859
R01 · FY2009 · CA · contact PI
BIOSYNTHETIC KEY STEPS OF ANGUCYCLINE ANTITUMOR DRUGS$7,403
R01 · FY2009 · CA · contact PI
Novel Aureolic Acid-Type Antitumor Agents$251,484
R01 · FY2008 · CA · contact PI
BIOSYNTHETIC KEY STEPS OF ANGUCYCLINE ANTITUMOR DRUGS$246,853
R01 · FY2008 · CA · contact PI
BIOSYNTHETIC KEY STEPS OF ANGUCYCLINE ANTITUMOR DRUGS$246,853
R01 · FY2007 · CA · contact PI
BIOSYNTHETIC KEY STEPS OF ANGUCYCLINE ANTITUMOR DRUGS$254,226
R01 · FY2006 · CA · contact PI
BIOSYNTHETIC KEY STEPS OF ANGUCYCLINE ANTITUMOR DRUGS$260,345
R01 · FY2005 · CA
NOVEL AUREOLIC ACID TYPE ANTITUMOR AGENTS$244,518
R01 · FY2005 · CA
NOVEL AUREOLIC ACID TYPE ANTITUMOR AGENTS$244,477
R01 · FY2004 · CA
NOVEL AUREOLIC ACID TYPE ANTITUMOR AGENTS$243,881
R01 · FY2002 · CA
NOVEL AUREOLIC ACID TYPE ANTITUMOR AGENTS$237,380
R01 · FY2002 · CA
NOVEL AUREOLIC ACID TYPE ANTITUMOR AGENTS$254,561
R01 · FY2001 · CA